Various studies have reported significant metabolic abnormalities in SMA animal models and patients such as altered fatty acid metabolism, hyperlipidemia, hyperglycemia, hyperglucagonemia increased hepatic insulin sensitivity, glucose intolerance, development of diabetes mellitus, diabetic ketoacidosis as well as glucose and insulin aberrations (16,26–33). This evidence concerns the gene INS and diabetic ketoacidosis.